139 related articles for article (PubMed ID: 3111056)
1. [Hormonal contraception with ethinylestradiol and gestoden. The effects on glucose tolerance and lipid metabolism].
Petersen KR; Skouby SO; Dreisler A; Kühl C
Ugeskr Laeger; 1987 Jun; 149(24):1614-6. PubMed ID: 3111056
[TBL] [Abstract][Full Text] [Related]
2. [Influence of progestins on adverse effects of oral contraceptives].
Wynn V
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
[TBL] [Abstract][Full Text] [Related]
3. Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene.
Lepot MR; Gaspard UJ
Int J Fertil; 1987; 32 Suppl():15-20. PubMed ID: 2906343
[TBL] [Abstract][Full Text] [Related]
4. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
6. [Combined estrogen-progestagen contraception and glucid and water-sodium metabolism].
Belaisch J; Hommais-loufrani B
Contracept Fertil Sex (Paris); 1988 Feb; 16(2):3-7. PubMed ID: 12342001
[TBL] [Abstract][Full Text] [Related]
7. [Comparative studies on oral glucose tolerance and serum lipids under the influence of a new oral contraceptive (SH B 209 AB: 2 mg cyproterone acetate + 0.05 mg ethinyl estradiol), the combination D-norgestrel/ethinyl estradiol and in a control group (author's transl)].
Schillinger E; Gerloff C; Wellershoff S; Wendt H; Lachnit-Fixson U
Arzneimittelforschung; 1976; 26(12):2242-5. PubMed ID: 1037282
[TBL] [Abstract][Full Text] [Related]
8. Oral contraceptives: effects on glucose and lipid metabolism in insulin-dependent diabetic women and women with previous gestational diabetes. A clinical and biochemical assessment.
Skouby SO
Dan Med Bull; 1988 Apr; 35(2):157-67. PubMed ID: 3282811
[TBL] [Abstract][Full Text] [Related]
9. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.
Skouby SO; Endrikat J; Düsterberg B; Schmidt W; Gerlinger C; Wessel J; Goldstein H; Jespersen J
Contraception; 2005 Feb; 71(2):111-7. PubMed ID: 15707560
[TBL] [Abstract][Full Text] [Related]
10. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253
[TBL] [Abstract][Full Text] [Related]
11. Clinical and metabolic effects of gestodene and levonorgestrel.
Rabe T; Runnebaum B; Kohlmeier M; Harenberg J; Weicker H
Int J Fertil; 1987; 32 Suppl():29-44. PubMed ID: 2906345
[TBL] [Abstract][Full Text] [Related]
12. The effect of low-oestrogen combined pill, progestogen-only pill and medroxyprogesterone acetate on oral glucose tolerance test.
Kamau RK; Maina FW; Kigondu C; Mati JK
East Afr Med J; 1990 Aug; 67(8):550-5. PubMed ID: 2148146
[TBL] [Abstract][Full Text] [Related]
13. Triphasic oral contraception: metabolic effects in normal women and those with previous gestational diabetes.
Skouby SO; Kühl C; Mølsted-Pedersen L; Petersen K; Christensen MS
Am J Obstet Gynecol; 1985 Nov; 153(5):495-500. PubMed ID: 3933351
[TBL] [Abstract][Full Text] [Related]
14. [Potential advantages of triphasic combined oral contraceptives in the light of recent epidemiological and endocrinometabolic data].
Gaspard U; Dubois M
Contracept Fertil Sex (Paris); 1982 Sep; 10(9):551-60. PubMed ID: 12311606
[TBL] [Abstract][Full Text] [Related]
15. Oral contraception and insulin sensitivity: in vivo assessment in normal women and women with previous gestational diabetes.
Skouby SO; Andersen O; Saurbrey N; Kühl C
J Clin Endocrinol Metab; 1987 Mar; 64(3):519-23. PubMed ID: 3102539
[TBL] [Abstract][Full Text] [Related]
16. Changes in insulin receptors during oral contraception.
De Pirro R; Forte F; Bertoli A; Greco AV; Lauro R
J Clin Endocrinol Metab; 1981 Jan; 52(1):29-33. PubMed ID: 7451643
[TBL] [Abstract][Full Text] [Related]
17. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
[TBL] [Abstract][Full Text] [Related]
18. Glucose and insulin levels after six months of treatment with a triphasic oral contraceptive containing ethinyl estradiol and norethindrone.
Spellacy WN; Ellingson AB; Tsibris JC
J Reprod Med; 1989 Aug; 34(8):540-2. PubMed ID: 2681750
[TBL] [Abstract][Full Text] [Related]
19. Oral contraceptives and insulin receptor binding in normal women and those with previous gestational diabetes.
Skouby SO; Andersen O; Kühl C
Am J Obstet Gynecol; 1986 Oct; 155(4):802-7. PubMed ID: 3766633
[TBL] [Abstract][Full Text] [Related]
20. [The triphasic pill].
Belaisch J
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):368-72. PubMed ID: 12280209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
